Lowest Price Guaranteed
Pages
250
Last Updated
July 2026
View Count
18369
The global cell therapy media market, valued at USD 1.6 billion in 2025, is projected to reach USD 1.8 billion in 2026 and USD 4.5 billion by 2035, with a 10.6% CAGR during the forecast period 2026 to 2035.
 |
To learn more about this report, request a free sample copy
The therapeutic approach involving the injection of healthy cells in the human body to replace the diseased / non-functioning cells, in order to regulate certain functions, is referred to as cell therapy. In the past few years, this therapeutic approach has emerged as one of the key areas of interest in the healthcare sector, given its ability to treat diseases which were previously considered untreatable. Consequently, driven by the benefits offered by cellular therapies and recent approvals granted by regulatory authorities, the demand for cellular therapies has increased considerably; this has led to a rise in the requirement of cell therapy raw materials. Specifically, cell therapy consumables refer to materials that are used in the manufacturing of cell therapies. It is worth mentioning that the selection of cell therapy consumables, specifically the cell culture media and supplements, is a crucial step in cell therapy manufacturing as they directly impact the potency and safety of the final product. In this cell culture consumables and cell culture media market report, we have considered the four predominant types of consumables applicable to cell therapy, namely cell culture media, media kits providing culture media along with the necessary media supplements, cell culture reagents and extracellular matrices.
The "Cell Culture Consumables and Cell Culture Media Market (2nd Edition): Industry Trends and Global Forecasts, till 2035" report features an extensive study of the current market landscape, market size and the likely future potential of the cell culture media (supplied alone or in kits as a combination with cell growth supplements), cell culture reagents and ECM market, over the forecast period. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the cell therapy industry. Key inclusions of the cell therapy consumables and cell culture media market report are briefly discussed below.
Please click on the thumbnail images to expand and view the details.
 |
 |
 |
Since the development of the first cell therapy, this therapeutic segment has garnered significant attention from researchers and medical practitioners. This can be attributed to the fact that cell therapies have been demonstrated to possess a vast potential in the treatment of rare disorders, which were previously considered incurable. The popularity of this therapeutic class of products can also be validated from the fact that, since 2019, more than 1,000 clinical trials focused on cell therapies have been initiated. It is also worth mentioning that over 35 cell and gene therapies have already been commercialized, across various geographical locations, till date. Notable examples of recently approved cell therapies include (in reverse chronological order) Breyanzi® (June 2022), Carvykti™ (February 2022) and Abecma® (March 2021).
Driven by the rise in popularity of cell therapies, there is a growth in demand for cell culture media, cell culture reagents and surfaces that support their production. It is worth mentioning that, amidst the increasing demand for such products, there is a rise in stringency from regulatory authorities to ensure that the quality of raw materials is good. Therefore, to meet the industry needs, cell therapy manufacturers are actively adopting serum free and xeno free products, which are known to reduce the risk of batch-to-batch variability.
Please click on the thumbnail images to expand and view the details.
 |
 |
 |
Currently, the marketed cell-based therapies are exorbitantly priced. Even though, with the introduction of automation technologies in cell therapy bioprocessing, the cost and time required for development of such products has reduced significantly, there is still a considerable scope of improvement to make these therapies affordable.
In this context, it is worth mentioning that consumables, including media, reagents and matrices, currently constitute nearly 25% of the overall cost of cell therapy manufacturing. Optimization of raw materials, by streamlining the production processes, can help mitigate wastage and further reduce the manufacturing cost. Moreover, for commercial applications, it is crucial to obtain consistent outcomes during the manufacturing process. Cell culture media, with chemically defined formulation, provides enhanced consistency for production purposes.
The cell therapy consumable providers market landscape features more than 80 companies, which claim to possess the necessary expertise for manufacturing of over 450 research and / or therapeutic grade raw materials. Some of these players also claim to have developed GMP certified facilities for the production of consumables, which are intended to be used for a range of human cells, including T-cells, stem cells, dendritic cells and NK cells. Subsequently, cell culture media market represents majority share (57%) of consumables offered, followed by the share captured by media and supplement kits (26%), extracellular matrices (14%) and cell culture reagents (3%). The ancillary materials offered by these companies are available in various volumes and can be utilized for numerous functions, such as cell proliferation, cell differentiation and cell isolation. Recent developments in cell culture consumables and cell culture media industry indicate that participants are actively expanding their capacity and product portfolio in order to accommodate the current and anticipated demand for cell therapies.
Please click on the thumbnail images to expand and view the details.
 |
 |
 |
In recent years, there has been a considerable rise in regulatory stringency as well as awareness related to disadvantages of using animal-based medica formulations, in the cell therapy domain. Specifically, animal-based media pose an undesirable risk of transfecting infectious agents. This has resulted in a shift towards the higher adoption of chemically defined, animal-component free (serum-free and xeno-free) media, in the cell culture media market. It is worth mentioning that, currently, majority of the cell culture media are being used for the development of stem cell therapies, followed by those intended for T-cell therapies.
One of the key drivers of the investments in this market is the success of previously commercialized cell therapies. More than USD 35 billion has already invested in cell therapy industry by private investors. In the last few years, cell therapies have offered a relatively more reliable approach for the treatment of rare diseases. According to a study published in 2019, the prevalence rate of rare diseases is about 263 to 446 million individuals, at any point of time. This necessitates the need for more such life-saving therapies. It is worth highlighting that, by 2030, close to 60 cell and gene therapies are anticipated to receive regulatory approval, further expanding the opportunities associated within the market. These factors will, in turn, lead to a surge in the requirement for quality consumables, driving significant market growth of the cell culture media industry.
Driven by the indubitably rising need for cell therapies, the market for cell culture media and other consumables for cell therapy manufacturing is anticipated to grow at a CAGR of 10.6%, during the forecast period, till 2035. Specifically, in terms of scale of operation, the demand for consumable products for commercial operations are expected to expand rapidly with the anticipated approval of numerous cell therapies. Additionally, it is worth highlighting that more than 80% of the current cell culture consumables and cell culture market share is captured by players based in North America and Asia-Pacific.
Examples of key companies engaged in this industry (which have also been captured in this report) include BD Biosciences, Bio-Techne, CellGenix, Corning, Irvine Scientific (Acquired by FUJIFILM), Lonza, Miltenyi Biotech, Sartorius, STEMCELL Technologies and Thermo Fisher Scientific. This cell culture consumables and cell culture media market analysis includes and easily searchable excel database of all the companies engaged in this industry, worldwide.
Several recent developments have taken place in the field of cell therapy consumables. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analyses.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Forecast Period |
|
|
| Current Market Size |
|
|
| Market Size 2035 |
|
|
|
CAGR |
|
|
| Type of Product |
|
|
| Type of Cell Therapy |
|
|
|
Scale of Operation |
|
|
|
Type of End-User |
|
|
|
Key Geographical Regions |
|
|
|
Key Companies Profiled |
|
|
|
Customization Scope |
|
|
|
PowerPoint Presentation (Complimentary) |
|
|
|
Excel Data Packs (Complimentary) |
|
|
The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different regions. Amongst other elements, the market report includes:
One of the key objectives of the market report was to estimate the current opportunity and the future growth potential of the cell culture consumables and cell culture media market over the coming years. We have provided an informed estimate on the likely evolution of the market for the forecast period, till 2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of product (kits, media, reagents and extracellular matrices), type of cell therapy (t-cell therapies, stem cell therapies, dendritic cell therapies and NK cell therapies), scale of operation (clinical and commercial), type of end-user (industry and non-industry) and key geographical regions (North America, Europe, Asia-Pacific, MENA and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in cell culture consumables and cell culture media industry. The market report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.